More Business Briefs
- Business briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN
- Business briefs: Novo Nordisk, Eli Lilly, Merck
- Business briefs: Medscape, Livestrong, ACA, Lilly
- Business briefs: Boehringer Ingelheim, Teva, Medicare
- Business briefs: GSK, DOJ, Sanofi, Flashpoint Medica
Victory Pharma has inked a deal with Hi-Tech Pharmacal for exclusive US commercial license rights to its Naprelan (naproxen sodium) formulation for the treatment of rheumatoid arthritis. The product will be marketed through Victory’s physician-based field sales force deployed throughout the US with plans for sales force expansion under way. Victory’s promotion of Naprelan is expected to begin during the first quarter of 2007.
Acorda Therapeutics said it has completed the expansion of its sales force to 65 people, 52 of whom are area business managers calling on specialists and primary care physicians. The Acorda sales team promotes Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For 2005, Acorda reported shipments of Zanaflex to wholesalers at $18.6 million, using its pilot sales force of 14 professionals. In March 2006, the company expanded its sales force to 32. Shipments to wholesalers increased to $31 million.
Galderma Laboratories announced the availability of a new MetroGel (metronidazole) Topical Gel kit for the topical treatment of the inflammatory lesions of rosacea.